All In Biotech

Drug Trial Radar · NCT01261494

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study.

Last checked: Nov 19, 2026Latest source record: Jul 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Dec 2010

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
GenfitIndustry
Sponsor type
Industry
First posted
Dec 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose. And to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 for 12 weeks in patients with type 2 diabetes mellitus.

Conditions

  • Type II Diabetes Mellitus

Interventions

  • GFT505 80mgDrug

    hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast

  • PlaceboDrug

    hard gelatin capsules,oral administration,4 capsules per day before breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: 12 weeks

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Site n°12

    Banja Luka, Bosnia and Herzegovina

  • Site n°11

    Sarajevo, Bosnia and Herzegovina

  • Site n°22

    Riga, Latvia

  • Site n°21

    Riga, Latvia

  • Site n°23

    Valmiera, Latvia

  • Site n°41

    Bălţi, Moldova

  • Site n°42

    Chisinau, Moldova

  • Site n°43

    Chisinau, Moldova

  • Site n°33

    Bitola, North Macedonia

  • Site n°31

    Skopje, North Macedonia

  • Site n°32

    Skopje, North Macedonia

  • Site n°67

    Bucharest, Romania

  • Site n°69

    Bucharest, Romania

  • Site n°68

    Bucharest, Romania

  • Site n°72

    Oradea, Bihor County, Romania

  • Site n°66

    Buzău, Buzău, Romania

  • Site n°64

    Cluj-Napoca, Cluj, Romania

  • Site n°65

    Baia Mare, Maramureş, Romania

  • Site n°63

    Târgu Mureş, Mureș County, Romania

  • Site n°62

    Târgu Mureş, Mureș County, Romania

  • Site n°71

    Ploieşti, Prahova, Romania

  • Site n°70

    Ploieşti, Prahova, Romania

  • Site n°61

    Sibiu, Sibiu County, Romania

  • Site n°52

    Belgrade, Serbia

  • Site n°53

    Belgrade, Serbia

  • Site n°56

    Belgrade, Serbia

  • Site n°54

    Kragujevac, Serbia

  • Site n°51

    Niš, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.